Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I posted that a while back. Just search my posts. Couple months ago.
But, soon to be rich groupies. I'll send you a picture of me not working. "Stay Tuned"!!!!
Well, both ONCS and Punit have tweeted that the abstract is now available online. We just might get a press release tomorrow. Stay tuned. lol.
I wrote them this morning and this was their response:
"Thanks for reaching out. We really appreciate the kind words and continued support. It is not our policy to comment on the timing and content of future press releases. Thanks again, and have a great weekend!"
Typical.
I think the question of a PR is complicated. On one hand, the effect on the pps at the conference would be greater. On the other hand, they are presenting at the ASCGT next week on the melanoma trial and wouldn't it be nice to mention the numbers that are already mentioned in the abstract (obviously they couldn't go further due to ASCO rules)? Also, they are now a featured presenter at the Marcum investor conference which would be a great place to promote data. I guess we will see.
Volume is back. This is so fun.
Well, looks like oncs didn't do a PR today. Will be an interesting day.
17 min. Totally excited!!!
Yah. I'm almost exclusively over here now unless Sal begs me to post over there or I'm making fun of mensa. You will really like it here.
Welcome. I'm jepetersonus over on yahoo.
Well Sal, it ain't coffee. And, I've never seen that many people in a picture holding water glasses. Dr. Bob nailed it!!!
You got to love a group that is drinking at 7:00 a.m.
I don't see his name there anymore.
See link:
http://bbbiotechconference.com/conference-agenda.php?id=23
Check out Punit's latest tweet:
http://t.co/Q3Qwwy2cgY
Looks like they are getting their R&D in Seattle going.
You may be right that the deals will be separate. However, I think that the deal is going to be for multiple trials.
I think it will be combination. That is what they have been stressing for a while not.
Here is the link:
http://www.medscape.com/viewarticle/823264
Don't forget Breast cancer. I can just see it now: Phase 2B melanoma and Phase I head and neck + breast cancer combination trials with MK-3475.
So, when it runs, it will really run.
Oncs' is not a late breaking abstract. It was submitted on time. I think it is today.
In my opinion, this might be the last day for cheap shares. As we all know, abstract comes out after trading today. I wish I had more money to buy.
In your estimation, how many total shares have been accumulated?
I don't think so. We are not a Late Breaking Abstract so I think we are fine. Should be tomorrow at 5:00 p.m.
I just got this e-mailed to me directly from the ASCO. It gives more detail on when information can be released.
http://www.asco.org/sites/www.asco.org/files/am_14_embargo_policy_change_notice_and_schedule_pr.pdf?et_cid=33758193&et_rid=828622644&linkid=here
I didn't know this, but ONCS has a new corporate update posted. It was posted on May 5, 2014. It is much more detailed. Good stuff.
http://content.stockpr.com/oncosec/media/3edbc526ab7184e1257fcbcac727954e.pdf
The way I read it is that right after the amended sg-3 was filed, the SEC approved it pretty much right away. So, from the SEC's purposes, we have a legal green light for issuing these shares to a partner or in an offering. I, of course, believe it is for a private placement in a partnership deal.
Did you guys notice that the registration was officially accepted by the SEC? Very cool. I'm sure most people will roll their eyes at me saying that this is a mere standard filing. I take it as the next step to partnership.
This are some good description:
1. https://answers.yahoo.com/question/index?qid=1006053006343
2.http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84024863
Here is the link to the filing:
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-195387&owner=exclude&count=200
It's the say it, explain it and say it again method.
Instead of guessing, here is the link:
"Patient/Public Resources
The 2014 ASCO Annual Meeting is the platform for the release of thousands of scientific abstracts -- highly anticipated research news for many people, including patients, caregivers, and the general public.
ASCO is pleased to share this timely information with the public in a variety of ways.
Get Timely News Highlights on Cancer.Net
Free patient-friendly summaries of research news highlights from this year’s Annual Meeting will be available via ASCO’s patient information website, Cancer.Net (www.cancer.net). Scientific news will be posted as soon as it becomes publicly available:
Easy-to-read summaries that put the top scientific news into context for patients, searchable by disease type or category
Videos and podcasts of national and international cancer experts, breaking down the science into specific disease areas and explaining what the studies mean for people with cancer
A section of related events and highlights from the ASCO Annual Meeting
To receive ASCO Annual Meeting breaking news via email, sign up now to receive the free newsletter Inside Cancer.Net. You can also follow Cancer.Net on Facebook, Twitter, or Google+ where real-time updates will also be sent out during the meeting.
News from the 2014 meeting will start to be released on May 14, 2014 at 5:00 PM EDT, with additional studies being released each day of the event, held May 30 to June 3."
http://am.asco.org/patientpublic-resources
Confidentiality agreement:
http://am.asco.org/confidentiality-policy
We both could be wrong. However, for our PPS on Friday, I hope you are wrong. I think you hope you are wrong too. :)
I hear you. I just think that ONCS could do a PR with the abstract and not violate any rules or cause in bad feelings with the conference in the future. I could be wrong (usually am :)).
Maybe, Maybe not. It is not like AACR though. At AACR, the company has the option to let the abstract be viewed early or participate in the scheduled media time-slot controlled by the conference. I remember calling the AACR about this because I was really interested in Merck's date for MK-3475 that was presented at AACR this year.
We will see.
Thanks. I don't see anything that would prevent ONCS from PRing the abstract. In fact, its what I expect. If the abstract is on the ASCO website with visibility to the public, why couldn't they publish to the investing public?
If they were able to PR the fact that they are accepted by ASCO, then certainly they would be able to PR the information that ASCO authorizes to be released.
Does anyone disagree with this? We could have some fireworks Thursday morning.
Tell them that they will need to find some more deductions after 6/3
Why can't they issue a PR with the abstract?
Could be. Partnership first. Let price go up. Do offering when price is right.
True. But the question is how to raise. Either share offering at a much higher price or partnership. I read it as partnership.
This the last thing I'll post on the S-3. Attached is a really good summary of Exhibit 5 legal opinions from the American Bar Association. Have a good weekend.
http://apps.americanbar.org/buslaw/tribar/materials/20050120000003.pdf
I still don't understand why they would need a second opinion but I guess we will find out in due time.
I went through some more of their filings and you are right. Morrison & Foerster LLP are ONCS' legal counsel (listed on their website as such). What is weird is that they didn't file the review letters in their previous S-1 filing in 8/16/2013 or 4/18/2014. But, for some reason they filed one in this amendment. No, I'm a bit confused. Sorry if I gave some of you false hope. I guess we will find out.
You are right. They are listed as counsel (on the first page) in both the S-1 filing from September 2013 and in the current S-3 filed on 4/18/2014. The difference is that they didn't do an "independent review" as in the current Amended S-3.